Physician profile
Anda Oprea
NPI 1164860565
$925.17
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $228 · 2023: $176 · 2024: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $586.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $329.40 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $127.66 | 2021-2024 | |
| Amgen INC. | $89.95 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.70 | 2024 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.22 | 2022-2023 | Xifaxan |
| Pfizer INC. | $49.78 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $47.79 | 2023-2024 | Breztri, Airsupra, Farxiga |
| Abbott Laboratories | $36.91 | 2021-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $20.85 | 2024 | Capvaxive, M-M-R II, Gardasil 9 |
| Lilly USA, LLC | $18.63 | 2024 | Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $16.99 | 2024 | Shingrix, Arexvy |
| Exact Sciences Corporation | $14.78 | 2023 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $14.13 | 2024 | Inspire |
| Janssen Pharmaceuticals, INC | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anda Oprea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.